Spectrum Pharmaceuticals to Participate in Three Upcoming Investor Conferences in January

Rhea-AI Summary

Spectrum Pharmaceuticals (NasdaqGS: SPPI) announced participation in three virtual investor conferences to showcase its business strategy and development-stage programs. Highlights include a fireside chat at the H.C. Wainwright BioConnect Conference available on-demand from January 11, 2021, a live presentation at the ICR Conference 2021 on January 14 at 1:45 p.m. ET, and another live fireside chat at the B. Riley Oncology Investor Conference on January 21 at 1 p.m. ET. Archived webcasts will be accessible on the company's investor relations website.

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will provide an overview of the company's business strategy and development-stage programs at three upcoming virtual investor conferences:

• H.C. Wainwright BioConnect Conference, a fireside chat will be available on-demand through the conference portal and on the Spectrum corporate website beginning Monday, January 11^th at 6 a.m. ET.

• ICR Conference 2021, presentation, live webcast, Thursday, January 14^th at 1:45 p.m. ET.

• B. Riley Oncology Investor Conference, fireside chat, live webcast, Thursday, January 21^st at 1 p.m. ET.

These events will be available from the Investor Relations section of the company’s website at http://investor.sppirx.com/events-and-presentations. An archived webcast will be available shortly after the ICR and B. Riley live events from the same website location.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. This pipeline has the potential to transform the company in the near future. For additional information on Spectrum Pharmaceuticals please visit www.sppirx.com.

Forward-looking statement — This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to Spectrum’s business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, the timing and results of FDA decisions, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that Spectrum’s existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the company's reports filed with the Securities and Exchange Commission. The company does not plan to update any such forward-looking statements and expressly disclaims any duty to update the information contained in this press release except as required by law.

SPECTRUM PHARMACEUTICALS, INC.^® is a registered trademark of Spectrum Pharmaceuticals, Inc and its affiliate. REDEFINING CANCER CARE™ and the Spectrum Pharmaceuticals logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.

© 2021 Spectrum Pharmaceuticals, Inc. All Rights Reserved

View source version on businesswire.com: https://www.businesswire.com/news/home/20210105005211/en/

FAQ

What will Spectrum Pharmaceuticals discuss at the virtual investor conferences?

Spectrum Pharmaceuticals will present its business strategy and development-stage programs at three virtual investor conferences.

When is the H.C. Wainwright BioConnect Conference for Spectrum Pharmaceuticals?

The H.C. Wainwright BioConnect Conference will have a fireside chat available on-demand starting January 11, 2021, at 6 a.m. ET.

What is the schedule for the ICR Conference 2021 for SPPI?

Spectrum Pharmaceuticals will present live at the ICR Conference 2021 on January 14, 2021, at 1:45 p.m. ET.

When will the B. Riley Oncology Investor Conference take place?

The B. Riley Oncology Investor Conference's live fireside chat will occur on January 21, 2021, at 1 p.m. ET.

Where can I find archived webcasts of Spectrum Pharmaceuticals' events?

Archived webcasts of Spectrum Pharmaceuticals' events will be available on the company's investor relations website following the live events.